In October 2007, the FDA introduced the labeling for all PDE5 inhibitors, like tadalafil, requires a more prominent warning of the opportunity chance of sudden Listening to reduction as the result of post-advertising studies of short term deafness linked to usage of PDE5 inhibitors.[19] Although